You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

SPORANOX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Sporanox patents expire, and what generic alternatives are available?

Sporanox is a drug marketed by Janssen Pharms and is included in three NDAs.

The generic ingredient in SPORANOX is itraconazole. There are fifteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the itraconazole profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Sporanox

A generic version of SPORANOX was approved as itraconazole by SANDOZ on May 28th, 2004.

  Try a Trial

Drug patent expirations by year for SPORANOX
Drug Prices for SPORANOX

See drug prices for SPORANOX

Recent Clinical Trials for SPORANOX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of ChicagoPhase 1
Arvinas Estrogen Receptor, Inc.Phase 1
Postgraduate Institute of Medical Education and ResearchN/A

See all SPORANOX clinical trials

Paragraph IV (Patent) Challenges for SPORANOX
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SPORANOX Oral Solution itraconazole 10 mg/mL 020657 1 2013-05-03

US Patents and Regulatory Information for SPORANOX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms SPORANOX itraconazole CAPSULE;ORAL 020083-001 Sep 11, 1992 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Janssen Pharms SPORANOX itraconazole INJECTABLE;INJECTION 020966-001 Mar 30, 1999 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Janssen Pharms SPORANOX itraconazole SOLUTION;ORAL 020657-001 Feb 21, 1997 AA RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SPORANOX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms SPORANOX itraconazole SOLUTION;ORAL 020657-001 Feb 21, 1997 ⤷  Try a Trial ⤷  Try a Trial
Janssen Pharms SPORANOX itraconazole CAPSULE;ORAL 020083-001 Sep 11, 1992 ⤷  Try a Trial ⤷  Try a Trial
Janssen Pharms SPORANOX itraconazole SOLUTION;ORAL 020657-001 Feb 21, 1997 ⤷  Try a Trial ⤷  Try a Trial
Janssen Pharms SPORANOX itraconazole INJECTABLE;INJECTION 020966-001 Mar 30, 1999 ⤷  Try a Trial ⤷  Try a Trial
Janssen Pharms SPORANOX itraconazole SOLUTION;ORAL 020657-001 Feb 21, 1997 ⤷  Try a Trial ⤷  Try a Trial
Janssen Pharms SPORANOX itraconazole SOLUTION;ORAL 020657-001 Feb 21, 1997 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for SPORANOX

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Avimedical B.V. Fungitraxx itraconazole EMEA/V/C/002722
For the treatment of aspergillosis and candidiasis in companion birds,
Authorised no no no 2014-03-12
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for SPORANOX

See the table below for patents covering SPORANOX around the world.

Country Patent Number Title Estimated Expiration
Denmark 160428 ⤷  Try a Trial
Japan H01211561 NITROGEN-CONTAINING HETEROCYCLIC GROUP SUBSTITUTED PHENYLPHYPERADINYL PHENOL ⤷  Try a Trial
Finland 961436 ⤷  Try a Trial
European Patent Office 0006712 HETEROCYCLIC DERIVATIVES OF (4-ARYLOXYMETHYL-1.3-DIOXOLAN-2-YL) METHYL-1H-IMIDAZOLES AND -1H-1.2.4-TRIAZOLES, THEIR PREPARATION AND THE DERIVATIVES FOR USE AS FUNGICIDES AND BACTERICIDES ⤷  Try a Trial
Poland 307791 ⤷  Try a Trial
Israel 81054 DERIVATIVES OF((4-(4-PHENYL-1-PIPERAZINYL)PHENOXYMETHYL)-1,3-DIOXOLAN-2-YL)METHYL)-1H-IMIDAZOLES AND 1H-1,2,4-TRIAZOLES,THEIR PREPARATION AND THEIR USE FOR COMBATING MICROORGANISMS ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.